[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, lumasiran (OXLUMO) is indeed used for the treatment of primary hyperoxaluria. Document [1] states that lumasiran is the first available, effective therapy for primary hyperoxaluria type 1 (PH1) and has been approved by the FDA for this indication. Document [4] also mentions that lumasiran is a medication for the treatment of PH1. Additionally, Document [12] describes a phase 3 trial where lumasiran was evaluated and found to reduce urinary oxalate excretion, the cause of progressive kidney failure in PH1. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]